Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 8.97 Billion |
| Market Size (2030) | USD 11.32 Billion |
| Growth Rate (2025 - 2030) | 4.76% CAGR |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
North America Contraceptives Market Analysis by Mordor Intelligence
The North America contraceptive market was valued at USD 8.97 billion in 2025 and is forecast to reach USD 11.32 billion by 2030, reflecting a 4.76% CAGR over the period. Growing regulatory support for over-the-counter products, wider digital-health integration, and persistent demand for long-acting reversible contraception are sustaining expansion despite legislative headwinds in parts of the United States.[1]U.S. Food and Drug Administration, “FDA Approves First Nonprescription Daily Oral Contraceptive,” fda.gov Consumers are shifting toward device-based options that avoid hormones, while insurers and public programs continue to prioritize cost-effective methods that lower unintended-pregnancy rates. Meanwhile, venture funding in male methods and AI-driven cycle-tracking applications is reshaping competitive strategies and enlarging the total addressable population. Across Canada and Mexico, universal-coverage initiatives and maternal-mortality targets are accelerating uptake, providing fresh growth channels for established and emerging brands.[2]World Health Organization, “Mexico,” who.int
Key Report Takeaways
- By product type, Devices held 61.56% of 2024 revenue, while pharmaceutical methods are set to grow the fastest at a 5.48% CAGR through 2030.
- By gender, Female-focused products captured an 87.57% share in 2024; the male segment is advancing at a 6.01% CAGR to 2030 as pipeline candidates progress.
- By hormonal class, Hormonal options commanded a 58.98% share in 2024, whereas non-hormonal methods led growth at a 5.86% CAGR through 2030.
- By geography, the United States accounted for 84.68% of sales in 2024; Mexico is the fastest-growing market, forecast at a 6.07% CAGR to 2030.
North America Contraceptives Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory approval for over-the-counter hormonal pills | +1.0% | United States; spillover to Canada | Short term (≤2 years) |
| Expanded Title X & Medicaid contraception budgets | +0.7% | United States (state variation) | Medium term (2-4 years) |
| Rising STI incidence boosts condom & LARC demand | +0.5% | Urban North America | Medium term (2-4 years) |
| Employer-backed telehealth benefits | +0.4% | United States, Canada | Short term (≤2 years) |
| Venture-funded male-method pipeline | +0.3% | United States; trials extend to Canada | Long term (≥4 years) |
| AI-powered cycle-tracking apps | +0.3% | United States, Canada | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Regulatory approval for OTC hormonal pills
The FDA clearance of Opill in 2023 significantly broadened access by removing prescription barriers, prompting insurers to debate zero-cost coverage and nudging manufacturers to re-evaluate pricing levers.[1]U.S. Food and Drug Administration, “FDA Approves First Nonprescription Daily Oral Contraceptive,” fda.gov Early sales data indicate incremental users rather than simple cannibalization, pointing to net market expansion.
Expanded Title X and Medicaid contraception budgets
Federal spending of USD 286.5 million for FY 2025 underpins safety-net clinics serving 2.8 million clients, though political uncertainty keeps providers cautious about long-term investments. Where funding is stable, private firms seize opportunities to partner with public programs.
Rising STI incidence boosts condom & LARC demand
CDC surveillance recorded 2.4 million reportable STI cases in 2023, spurring dual-protection counseling and anchoring condoms as an essential complement to LARCs.[3]Centers for Disease Control and Prevention, “National Overview of STIs in 2023,” cdc.gov The trend is especially pronounced among the 15-24 age group.
Employer-backed telehealth benefits
Digital clinics funded by employer insurance now ship prescriptions to 43 US states, shortening wait times and widening Medicaid reach. Institutional protocols developed at UCSF confirm the staying power of tele-contraception.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Post-Dobbs state-level legal uncertainty | −1.1% | Restrictive US states | Medium term (2-4 years) |
| Social-media misinformation on hormonal side effects | −0.7% | United States, Canada | Short term (≤2 years) |
| Supply-chain shocks for levonorgestrel IUDs | −0.6% | North America | Short term (≤2 years) |
| Reimbursement caps on advanced LARCs | −0.4% | United States (Medicaid variation) | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Post-Dobbs legal uncertainty dampens provider availability
States enforcing abortion restrictions saw 5.6% drops in birth-control prescriptions and clinic closures that limit contraceptive counseling capacity.
Social-media misinformation on hormonal side effects
Viral myths on mood change and infertility have led some users to abandon reliable hormonal options, prompting ACOG to ramp up fact-checking campaigns.
Segment Analysis
By Products: Devices drive market leadership
Contraceptive devices held 61.56% of the North America contraceptive market in 2024 on the strength of long-acting IUDs and hormone-free barrier methods. The segment benefits from nonprofit price reductions such as Medicines360’s LILETTA under the 340B program.[4]U.S. Government Accountability Office, “Information on Funding, Drug Types, Challenges, and Reported Effect,” gao.gov Condoms retain relevance due to dual-protection needs amid STI spikes.
Pharmaceutical methods, though smaller, are pacing a 5.48% CAGR to 2030. The North America contraceptive market size for pills, patches, and injectables is expanding after OTC approval of Opill, while safety revisions around DMPA reshape prescribing patterns.
Note: Segment shares of all individual segments available upon report purchase
By Gender: Male segment emergence challenges female dominance
Female-oriented products accounted for 87.57% of the North America contraceptive market share in 2024, reflecting entrenched clinical norms and broad product ranges. New offerings, such as the once-weekly Twirla patch, aim to ease adherence.
The North America contraceptive market sees male methods growing at 6.01% CAGR, catalyzed by Plan A and other non-hormonal candidates that could reach FDA review within three years. Surveys show men are willing to adopt novel reversible options, indicating latent demand.
By Hormonal Class: Non-hormonal innovation accelerates
Hormonal solutions controlled 58.98% of sales in 2024. Decades of safety data and insurance coverage maintain consumer confidence, yet misinformation and emerging safety signals for certain injectables temper growth.
Non-hormonal offerings are on a 5.86% CAGR path as users seek hormone-free alternatives. Candidates such as Ovaprene underline the innovation focus, while copper IUDs stay popular for long-acting, drug-free protection.
Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
The United States generated 84.68% of 2024 revenue, supported by the world’s largest insurance market and rapid consumer uptake following OTC pill authorization. Yet the post-Dobbs legal patchwork depresses sales in restrictive states, creating uneven channel performance.
Canada’s universal-coverage roadmap, backed by CAD 670 million in federal-provincial funding, positions the country for steady uptake once reimbursement begins in 2026. Pharmacist prescribing launched in British Columbia already logged more than 430,000 assessments, demonstrating demand for decentralized access.
Mexico is the fastest-growing territory at 6.07% CAGR thanks to WHO-backed maternal-mortality programs and a streamlined COFEPRIS clinical-trial process that invites foreign investment.
Competitive Landscape
Legacy manufacturers such as Bayer, Pfizer, and Johnson & Johnson rely on scale and multichannel reach to defend positions, yet face margin pressure from nonprofit price disruptors like Medicines360. Telehealth-centric entrants, exemplified by Twentyeight Health, are winning Medicaid contracts in 43 states and bypassing brick-and-mortar constraints.
Male-method R&D is the new white space: Plan A and other startups are racing to secure pivotal data ahead of anticipated FDA guideline updates for male contraception pathways. Agile Therapeutics’ pivot to e-commerce and high-reimbursement states illustrates how incumbents adapt to fragmented insurance rules.
Technology remains the defining battleground; firms integrating AI analytics, wearable sensors, and same-day delivery stand to capture loyalty as consumers expect seamless experiences. Those able to navigate varying state laws while scaling digital services will likely out-pace slower, compliance-burdened rivals.
North America Contraceptives Industry Leaders
-
Bayer AG
-
Teva Pharmaceuticals Ltd
-
Pfizer
-
Cooper Surgical
-
Reckitt Benckiser Group plc
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- February 2025: FDA approved MIUDELLA copper IUS for pregnancy prevention up to three years.
- February 2025: Reya Health launched an education app that matches Canadians with suitable methods via algorithms.
- February 2025: Slynd tablets gained reimbursement in eight Canadian provinces and several federal programs.
- January 2025: 49Care introduced Yanae copper IUD across Canadian pharmacies.
Research Methodology Framework and Report Scope
Market Definitions and Key Coverage
Our study defines the North America contraceptives market as all prescription and over-the-counter drugs (oral, injectable, topical) and devices, including condoms, IUDs, implants, vaginal rings, diaphragms, and sponges, that are marketed for pregnancy prevention or dual protection across the United States, Canada, and Mexico.
Excluded scope: fertility-tracking apps, surgical sterilization, and abortifacients are not considered.
Segmentation Overview
- By Products
- Drugs
- Oral Contraceptives
- Topical Contraceptives
- Contraceptive Injectables
- Devices
- Condoms
- Diaphragms
- Cervical Caps
- Sponges
- Vaginal Rings
- Intrauterine Devices
- Other Devices
- Drugs
- By Gender
- Male
- Female
- By Hormonal Class
- Hormonal Methods
- Non-Hormonal Methods
- Geography
- United States
- Canada
- Mexico
Detailed Research Methodology and Data Validation
Primary Research
Mordor analysts interviewed obstetricians-gynecologists, Title X clinic directors, retail pharmacy buyers, and device distributors in all three countries. Their insights clarified OTC pill uptake rates, distributor mark-ups, and LARC insertion backlogs, letting us fine-tune assumptions before locking the model.
Desk Research
We began with population and usage datasets from the CDC National Survey of Family Growth, Statistics Canada, Mexico's ENSANUT, UNFPA, and regulatory approval logs from the US FDA, Health Canada, and COFEPRIS. We then mapped product uptake and pricing trends. Trade statistics from UN Comtrade, retail scanner panels, and customs HS codes refined volume splits, while company sell-out values were screened through D&B Hoovers and Dow Jones Factiva. Context on unmet need and policy shifts was drawn from the Guttmacher Institute and peer-reviewed journals in Obstetrics & Gynecology. These references are illustrative; many additional public and subscription sources supported desk analysis.
Market-Sizing & Forecasting
A top-down construct starts with the reproductive-age female pool, applies modern contraceptive prevalence and method shares, and then multiplies by net average selling prices. Sampled manufacturer revenues and channel checks act as a bottom-up reasonableness screen. Key variables include insurance coverage ratios, OTC switch timelines, peso-dollar exchange trends, telehealth prescription share, and public funding outlays. Forecasts for 2025-2030 rely on multivariate regression keyed to female employment growth and GDP per capita, with scenario analysis for major policy shocks.
Data Validation & Update Cycle
Outputs are matched against historical sales series, public procurement notices, and import tallies; variance flags trigger analyst re-runs and supervisory review. Reports are updated annually, with interim refreshes after material regulatory or product events to keep clients current.
Why Mordor's North America Contraceptives Baseline Earns Trust
Published figures often diverge because providers choose different product baskets, price points, or refresh cadences.
The contrasts below make those gaps clear.
Benchmark comparison
| Market Size | Anonymized source | Primary gap driver |
|---|---|---|
| USD 8.97 B (2025) | Mordor Intelligence | - |
| USD 9.58 B (2024) | Regional Consultancy A | List prices and fixed 2022 FX rates inflate totals |
| USD 8.30 B (2022) | Industry Journal B | Older base year, excludes clinic volumes |
| USD 9.10 B (2024) | Global Consultancy C | Devices only, omits hormonal drugs |
The comparison shows that our disciplined scope choices, current base year, and dual-track validation give decision-makers a balanced, transparent baseline they can trace and replicate with confidence.
Key Questions Answered in the Report
1. What is the current value of the North America contraceptive market?
The market generated USD 8.97 billion in 2025 and is projected to climb to USD 11.32 billion by 2030.
2. Which product category holds the largest share?
Devices such as IUDs and condoms led with 61.6% revenue share in 2024.
3. How will male contraceptives influence growth?
Male methods are forecast to grow at 6.0% CAGR, supported by new non-hormonal technologies now in clinical trials.
4. Why are digital platforms important to contraceptive access?
Telehealth and AI-driven apps shorten wait times and personalize choices, expanding reach especially in rural areas
5. What regulatory change most strongly affects market dynamics?
The FDA’s over-the-counter approval of Opill removed prescription barriers and is expected to add 1.0% to the market’s CAGR.
6. Which country in North America is growing the fastest
Mexico shows the highest forecast growth at 6.07% CAGR through 2030, buoyed by WHO-supported maternal-health programs.
Page last updated on:
